Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVL218 combination therapy in advanced solid tumors
NCT06078670Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Oct 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of mefuparib in triple-negative breast cancer (TNBC), gastric cancer (GC) and colorectal cancer (CRC) (3 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Incidence of dose-limiting toxicity at 6 months. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
mefuparib
03
Conditions
triple-negative breast cancer (TNBC)gastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06078670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06078670.